20 results about "Human coronavirus" patented technology

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and / or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and / or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

The invention discloses an application of an eIF2alpha kinase regulator in preparation of an anti-human coronavirus drug. Specifically, the compound provided by the invention has the activity of resisting human coronavirus HCoV-OC43 and / or resisting new coronavirus of human coronavirus. The invention focuses on antiviral host factors, provides a target compound for targeting host eIF2alpha kinase, eIF2alpha phosphorylation and protein synthesis, plays an antiviral role by accurately regulating and controlling host virus interaction, and is beneficial to overcoming virus resistance and obtaining broad-spectrum antiviral activity.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

Antimicrobial compositions include a therapeutically effective amount of neem oil, extract of the plant Hypericum spp., polyunsaturated fatty acids (PUFAs), carrageenans, and / or chlorhexidine; and (optionally) in combination with one or more pharmaceutically acceptable carriers, additives, and / or diluents. The antimicrobial compositions are effective in treating or preventing upper respiratory tract infections, preferably upper respiratory tract infections caused by human Coronaviruses and are included within methods of treating or preventing infection of the upper respiratory tract of humans by a microbial pathogen.

The invention discloses a primer probe, a method and application for detecting human coronavirus OC43. The nucleic acid sequence of the primer comprises the sequences as shown in SEQ ID NO. 7 to SEQ ID NO. 8; the nucleic acid sequence of the fluorescent probe comprises a sequence as shown in SEQ ID NO.9. The primer and the fluorescent probe for detecting the human coronavirus OC43 are creatively designed, the human coronavirus OC43 inactivated virus standard substance can be accurately detected by using the primer, the probe and the digital valuing method, the sensitivity is high, and the specificity is strong.

Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2 / COVID-19 cases.

The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

The invention discloses an expression vector, a cell and a vaccine of multivalent coronavirus recombinant protein and a preparation method of the multivalent coronavirus recombinant protein, and relates to the technical field of preparation of protein vaccines of coronavirus. A recombinant protein technical means is utilized to prepare a novel multivalent coronavirus recombinant protein, the novel multivalent coronavirus recombinant protein is prepared into a candidate vaccine, the candidate vaccine can induce an organism to generate immunoreactions aiming at different mutant strains of beta new coronavirus and alpha human coronavirus, and the generated immunoreactions are humoral immunity, cellular immunity and / or mucosal immunity. Therefore, the expression vector and the recombinant cell for expressing the novel multivalent coronavirus recombinant protein, provided by the invention, have a good application prospect. The vaccine containing the multivalent coronavirus recombinant protein has a wider coronavirus protection spectrum, the application range of the vaccine is expanded, and the vaccine has a good immunogenicity enhancing effect.

The invention belongs to the technical field of microbial preparation of compounds. The polyketone compound provided by the invention shows excellent inhibitory activity on influenza A virus (IAV), human coronavirus (OC43) and ZIKV (Zika virus). The polyketone compound provided by the invention has any chemical structural formula shown in the specification.

The invention provides a method for extracting and enriching phenylethanoid glycoside and lignan effective components from fructus forsythiae fresh leaves. The method comprises the following steps: extracting phenylethanoid glycoside and lignan compounds, enriching MCI resin components, analyzing by liquid chromatography-mass spectrometry, and identifying. The enrichment extracted by the method provided by the invention is a mixture containing phenylethanoid glycoside and lignan compounds respectively, and can be used as a medicine for resisting the human coronavirus HCoV-229E.

The invention discloses a 2 '-fluoro-4'-alkynyl-6-methylmercapto substituted nucleoside derivative as well as a preparation method and application thereof, the structure of the 2 '-fluoro-4'-alkynyl-6-methylmercapto substituted nucleoside derivative is shown as a general formula (xv), and X and Y are independently selected from-H, C1-10 alkyl, halogen,-CN,-N3,-OH or-NH2. Compared with the prior art, the invention provides the 2 '-fluoro-4'-alkynyl-6-methylmercapto substituted nucleoside derivative with a novel structure, and compared with a similar compound disclosed in the prior art, the 2 '-fluoro-4'-alkynyl-6-methylmercapto substituted nucleoside derivative has obviously better anti-coronavirus activity. Experimental results show that the compound disclosed by the invention can effectively inhibit human coronavirus HCoV-229E and has a good application prospect in the aspect of treating coronavirus infection. (xv).

Synthetic MVA-based vaccine compositions for preventing or treating a virus infection such as a coronavirus infection and methods of producing the vaccines. The vaccine compositions include (i) either a single DNA fragment that includes the entire genome of MVA, or two or more DNA fragments, each including a partial sequence of the genome of the MVA such that the two or more DNA fragments, when expressed in the host cell upon co-transfection, are assembled sequentially and comprise the full-length sequence of the MVA genome, and (ii) one or more DNA sequences encoding one or more human coronavirus antigens, subunits, or fragments thereof inserted in one or more insertion sites of the MVA. The antigens, subunits, or fragments thereof are expressed in the host cell upon transfection of the one or more DNA fragments.

The invention belongs to the technical field of plant extract preparations, and discloses a plant disinfectant and a preparation method thereof. The preparation method comprises the following preparation steps: (1) mixing and crushing dried liquorice, fructus forsythiae, radix isatidis, honeysuckle, dandelion, golden cypress, cyrtomium fortunei, andrographis paniculata and oldenlandia diffusa, and then adding into hot water for standing and soaking treatment; and (2) filtering the mixture soaked in the step (1), filling a percolation column with a wet solid material, and performing low-temperature percolation extraction at the temperature of 0-30 DEG C by adopting an ethanol water solution as an extraction solvent to obtain the plant disinfectant. The preparation method of the plant disinfectant is simple, the process conditions are easy to control, and the production cost is low. Through verification, good killing effects on candida albicans, staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, tortoise mycobacterium abscess subspecies, natural bacteria, human coronavirus and influenza A virus can be achieved.

The application provides a pharmaceutical composition, which comprises an antiviral peptide conjugate, for the treatment or prevention of a condition or disease associated with a coronaviral infection. The coronavirus includes human coronavirus OC43, human coronavirus HKU1, human coronavirus 229E, human coronavirus NL63, Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, SARS-CoV-2, or any variant thereof. The pharmaceutical composition is designed for, inter alia, intranasal administration.

The application discloses a novel photocatalytic plate and a preparation method, application and plate filter and disinfecting method thereof, the photocatalytic plate is prepared by a solvothermal method to prepare a TiO2 doped BiOI composite material, and is combined with iron-nickel ceramics, and is loaded on a porous metal base by adopting a 'two-time glazing + segmented drying + high-temperature rapid sintering' process. The heterojunction structure formed by TiO2 and BiOI effectively widens the light response range and inhibits the electron-hole pair recombination. In combination with the full-coating structure of the plate filter, the application shows excellent activity in the disinfection of human coronavirus and influenza A virus.

Methods for detecting nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are described. The methods comprise amplifying nucleic acid of a sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an isothermal amplification reaction using a forward nucleic acid amplification primer and a reverse nucleic acid amplification primer, wherein each nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, or the complement thereof. The methods are particularly useful for point-of-care (ROC) testing. Kits, primers, probes, sets of primers, sets of oligonucleotides, and oligonucleotides, and their use in the methods are also described.

The application discloses application of shikonin or a derivative thereof in preparation of a medicine for treating coronavirus infection, and the mutant strains include a delta mutant strain and an omicron mutant strain of human coronavirus SARS-CoV-2. The application further discloses a medicine combination and application thereof, and the medicine combination comprises two or more than two kinds of shikonin or derivatives thereof. The shikonin or the derivative thereof has obvious in-vitro inhibitory effect on main proteases of the coronavirus, and shows broad-spectrum antiviral effect.

The application belongs to the technical field of biological medicine, and discloses the use of a BCAT2 inhibitor in the preparation of a drug for preventing, relieving and / or treating a disease related to a coronavirus infection, and specifically discloses the use of a BCAT2 inhibitor BAY-069 in the prevention and / or treatment of a disease related to murine hepatitis virus (MHV) or human coronavirus 229E infection, thereby providing a new strategy for developing broad-spectrum antiviral drugs.